Clinical trial TG6002.02
A Phase I/IIa study of TG6002 (VV TK-RR-FCU1) administered by intravenous (IV) infusions in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2a |
| Academic trial | Non |
| Sponsor | Transgene S.A. |
| EudraCT Identifier | 2018-000039-28 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03724071 |
| Inclusion criteria | After standard therapy / RECIST 1.1 |
| Last update |